Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

doi:10.1038/s41467-026-74711-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications - 23 Jun 2026

Wang Hejia Henry, Huff Amanda L, Haldar S Daniel, Berg Maureen, Thoburn Christopher, Heumann Thatcher R, Anders Robert A, Barrett Benjamin, Bever Katherine M, Pishvaian Michael J, Lee Valerie, Le Dung T, Christenson Eric S, Baretti Marina, Yarchoan Mark, Laheru Daniel, Thomas Amy, Durham Jennifer N, Nauroth Julie M, Lu Jiayun, Wang Hao, Jaffee Elizabeth M, Azad Nilofer S, Zaidi Neeha

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have limited activity in mismatch repair proficient or microsatellite stable (MMRp/MSS) colorectal cancer (CRC). KRAS mutations, present in approximately 40% of these cancers, can generate neoantigens that are targets for therapeutic vaccines. In this single-arm, phase I study (NCT04117087), we evaluated mKRAS-VAX, a pooled mutant KRAS (mKRAS) peptide vaccine targeting six KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Colorectal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Ipilimumab

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to Vaccines, Subunit

Source

Open in PubMed Open full text

Identifiers

PMID: 42336869
DOI: 10.1038/s41467-026-74711-8
PMCID: PMC13444141

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.PMID 42336869Read ↗

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.Semantic proximity Read ↗

A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation.Semantic proximity Read ↗

Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review)Semantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Semantic proximity Read ↗

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkersSemantic proximity Read ↗

The future of cancer vaccines against colorectal cancerSemantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.